Patients with increasing tumor burden had significantly higher % 53BP1+ cells at baseline (61 ± 16% (range, 35–78%) vs. 43 ± 16%, (range, 17–63%); p = 0.0361) (Figure 5). Here, TP53BP1 is linked to neoplasm.